
    
      The study contains 3 cohorts of 12 participants each: All participants will be orally
      administered for 105 days with CBD at doses of 75, 150 or 300 mg (PO) BID for the prevention
      of acute GVHD (aGVHD) following allogeneic HSCT.

      In addition to the study drug, all participants will receive standard aGVHD prophylaxis
      consisting of a calcineurin inhibitor (cyclosporine or tacrolimus) and a short course of
      methotrexate (MTX). After completion of 105 treatment days, the participant will be
      followed-up until day 180.
    
  